系统性硬化症临床表现的种族差异:EUSTAR队列研究
该研究基于EUSTAR队列,横断面比较白人、亚洲及黑人系统性硬化症患者的临床特征。亚洲患者疾病起始更快、抗拓扑异构酶I抗体阳性率较高、肺动脉高压和肺功能受损更常见且死亡风险更高;黑人患者疾病起始最快、弥漫性皮肤受累更多、死亡风险最高。
要点
- 亚洲患者较白人患者疾病起始更快,肺动脉高压和FVC下降风险更高。
- 黑人患者疾病起始最快,弥漫性皮肤受累比例更高,死亡风险最高。
- 种族差异大多独立于地理区域,提示遗传或环境因素可能起作用。
核心结论
- 与白人患者相比,亚洲患者疾病起始更快更早,ATA阳性率较高,肺动脉高压和FVC受损更常见,死亡率更高,且大多独立于地理区域。
- 黑人患者疾病起始最快,弥漫性皮肤受累比例高,死亡风险最高。
研究设计与样本
- 基于EUSTAR队列的横断面研究,纳入9162例白人患者、341例亚洲患者和181例黑人患者,采用生存分析和多重逻辑回归比较种族组间SSc特征。
主要发现
- 亚洲患者出现首个非雷诺现象特征快于白人但慢于黑人。
- 亚洲患者ACA阳性率较低(OR=0.4,P<0.001),ATA阳性率较高(OR=1.2,P=0.068);黑人患者ACA(OR=0.3,P<0.001)和ATA(OR=0.5,P=0.020)阳性率均低于白人。
- 亚洲患者弥漫性皮肤受累较少(OR=0.7,P=0.06),黑人患者较多(OR=2.7,P<0.001)。
- 亚洲和黑人患者肺动脉高压风险较高(OR=2.6,P<0.001;OR=2.7,P=0.03)且FVC下降风险较高(OR=2.5,P<0.001;OR=2.4,P<0.004)。
- 亚洲患者DLCO受损较黑人和白人更常见(OR=1.9,P=0.038;OR=2.4,P<0.001);雷诺现象起病后亚洲和黑人患者死亡风险高于白人(HR=1.6,P=0.011;HR=2.1,P<0.001)。
临床怎么用
- 对亚洲和黑人SSc患者应更警惕肺动脉高压和肺功能受损,早期筛查和密切监测。
- 黑人患者需关注弥漫性皮肤受累及更高死亡风险,加强综合管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Racial factors play a significant role in SSc. We evaluated differences in SSc presentations between white patients (WP), Asian patients (AP) and black patients (BP) and analysed the effects of geographical locations. METHODS: SSc characteristics of patients from the EUSTAR cohort were cross-sectionally compared across racial groups using survival and multiple logistic regression analyses. RESULTS: The study included 9162 WP, 341 AP and 181 BP. AP developed the first non-RP feature faster than WP but slower than BP. AP were less frequently anti-centromere (ACA; odds ratio (OR) = 0.4, P < 0.001) and more frequently anti-topoisomerase-I autoantibodies (ATA) positive (OR = 1.2, P = 0.068), while BP were less likely to be ACA and ATA positive than were WP [OR(ACA) = 0.3, P < 0.001; OR(ATA) = 0.5, P = 0.020]. AP had less often (OR = 0.7, P = 0.06) and BP more often (OR = 2.7, P < 0.001) diffuse skin involvement than had WP. AP and BP were more likely to have pulmonary hypertension [OR(AP) = 2.6, P < 0.001; OR(BP) = 2.7, P = 0.03 vs WP] and a reduced forced vital capacity [OR(AP) = 2.5, P < 0.001; OR(BP) = 2.4, P < 0.004] than were WP. AP more often had an impaired diffusing capacity of the lung than had BP and WP [OR(AP vs BP) = 1.9, P = 0.038; OR(AP vs WP) = 2.4, P < 0.001]. After RP onset, AP and BP had a higher hazard to die than had WP [hazard ratio (HR) (AP) = 1.6, P = 0.011; HR(BP) = 2.1, P < 0.001]. CONCLUSION: Compared with WP, and mostly independent of geographical location, AP have a faster and earlier disease onset with high prevalences of ATA, pulmonary hypertension and forced vital capacity impairment and higher mortality. BP had the fastest disease onset, a high prevalence of diffuse skin involvement and nominally the highest mortality.
引用
- Jaeger VK, Tikly M, Xu D, et al. Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. Rheumatology (Oxford). 2020. PMID: 31680161. doi:10.1093/rheumatology/kez486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。